Advertisement
DVAX vs ESALF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a StrongBuy and ESALF is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DVAX’s FA Score shows that 0 FA rating(s) are green whileESALF’s FA Score has 2 green FA rating(s).
- DVAX’s FA Score: 0 green, 5 red.
- ESALF’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ESALF’s TA Score has 6 bullish TA indicator(s).
- DVAX’s TA Score: 4 bullish, 4 bearish.
- ESALF’s TA Score: 6 bullish, 2 bearish.
Price Growth
DVAX (@Pharmaceuticals: Generic) experienced а -4.02% price change this week, while ESALF (@Pharmaceuticals: Generic) price change was +9.49% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.75%. For the same industry, the average monthly price growth was +0.65%, and the average quarterly price growth was +19.08%.
Reported Earning Dates
DVAX is expected to report earnings on Feb 19, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+1.75% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| DVAX | ESALF | DVAX / ESALF | |
| Capitalization | 1.29B | 8.48B | 15% |
| EBITDA | -34.26M | 104B | -0% |
| Gain YTD | -14.096 | 16.777 | -84% |
| P/E Ratio | 54.60 | 26.71 | 204% |
| Revenue | 316M | 789B | 0% |
| Total Cash | 614M | 266B | 0% |
| Total Debt | 285M | 188B | 0% |
DVAX | ESALF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 35 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 67 | 100 | |
SMR RATING 1..100 | 93 | 6 | |
PRICE GROWTH RATING 1..100 | 52 | 73 | |
P/E GROWTH RATING 1..100 | 97 | 58 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ESALF's Valuation (9) in the null industry is somewhat better than the same rating for DVAX (68) in the Biotechnology industry. This means that ESALF’s stock grew somewhat faster than DVAX’s over the last 12 months.
DVAX's Profit vs Risk Rating (67) in the Biotechnology industry is somewhat better than the same rating for ESALF (100) in the null industry. This means that DVAX’s stock grew somewhat faster than ESALF’s over the last 12 months.
ESALF's SMR Rating (6) in the null industry is significantly better than the same rating for DVAX (93) in the Biotechnology industry. This means that ESALF’s stock grew significantly faster than DVAX’s over the last 12 months.
DVAX's Price Growth Rating (52) in the Biotechnology industry is in the same range as ESALF (73) in the null industry. This means that DVAX’s stock grew similarly to ESALF’s over the last 12 months.
ESALF's P/E Growth Rating (58) in the null industry is somewhat better than the same rating for DVAX (97) in the Biotechnology industry. This means that ESALF’s stock grew somewhat faster than DVAX’s over the last 12 months.
| DVAX | ESALF | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 80% | 7 days ago 41% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 36% |
| Momentum ODDS (%) | 2 days ago 66% | 2 days ago 41% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 44% |
| TrendWeek ODDS (%) | 2 days ago 74% | 2 days ago 41% |
| TrendMonth ODDS (%) | 2 days ago 74% | 2 days ago 49% |
| Advances ODDS (%) | 2 days ago 76% | 2 days ago 40% |
| Declines ODDS (%) | 7 days ago 77% | about 1 month ago 70% |
| BollingerBands ODDS (%) | 2 days ago 78% | 7 days ago 36% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 76% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NIXT | 26.79 | 0.39 | +1.48% |
| Research Affiliates Deletions ETF | |||
| SMMV | 43.13 | 0.14 | +0.33% |
| iShares MSCI USA Sm-Cp Min Vol Fctr ETF | |||
| BSCV | 16.73 | 0.03 | +0.18% |
| Invesco BulletShares 2031 Corp Bd ETF | |||
| HIDE | 23.48 | 0.04 | +0.17% |
| Alpha Architect High Infl And Defltn ETF | |||
| JJETF | 5.50 | N/A | N/A |
| Barclays Bank PLC | |||
DVAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.
| Ticker / NAME | Correlation To DVAX | 1D Price Change % | ||
|---|---|---|---|---|
| DVAX | 100% | +0.83% | ||
| ACET - DVAX | 39% Loosely correlated | -4.12% | ||
| SNDL - DVAX | 35% Loosely correlated | +2.35% | ||
| ALKS - DVAX | 32% Poorly correlated | +1.93% | ||
| COLL - DVAX | 28% Poorly correlated | +0.72% | ||
| TLRY - DVAX | 27% Poorly correlated | -8.43% | ||
More | ||||
ESALF and
Correlation & Price change
A.I.dvisor tells us that ESALF and ESAIY have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ESALF and ESAIY's prices will move in lockstep.
| Ticker / NAME | Correlation To ESALF | 1D Price Change % | ||
|---|---|---|---|---|
| ESALF | 100% | +2.56% | ||
| ESAIY - ESALF | 26% Poorly correlated | -1.38% | ||
| DVAX - ESALF | 23% Poorly correlated | +0.83% | ||
| KHTRF - ESALF | 22% Poorly correlated | N/A | ||
| SHPH - ESALF | 22% Poorly correlated | -9.37% | ||
| BLMH - ESALF | 21% Poorly correlated | -1.52% | ||
More | ||||